Amgen Inc.
TRANSTHYRETIN IMMUNOGLOBULIN FUSIONS
Last updated:
Abstract:
The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein.
Status:
Application
Type:
Utility
Filling date:
3 Oct 2018
Issue date:
8 Oct 2020